133057-82-6

Basic information

• Product Name: 4-BENZYLOXY-3-FLUORO-BROMOBENZENE
• Synonyms: 1-Bromo-4-benzyloxy-3-fluorobenzene
• CAS NO: 133057-82-6
• Molecular Formula: C₁₃H₁₀BrFO
• Molecular Weight: 281.13
• Product Categories: alkyl bromide|alkyl Fluorine
• Mol File: 133057-82-6.mol

Chemical Properties

• Boiling Point: 345.44 °C at 760 mmHg
• Flash Point: 194.281 °C
• Appearance: /
• Density: 1.445 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.584
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 4-BENZYLOXY-3-FLUORO-BROMOBENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BENZYLOXY-3-FLUORO-BROMOBENZENE(133057-82-6)
• EPA Substance Registry System: 4-BENZYLOXY-3-FLUORO-BROMOBENZENE(133057-82-6)

Safety Data

• Hazardous Substances Data: 133057-82-6(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
4-BenzylOxy-3-Fluoro-Bromobenzene is used as a chemical intermediate in the field of organic synthesis. Its unique structure, which includes bromine, fluorine, and benzyl groups, makes it a valuable component in the creation of more complex chemical compounds.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 4-BenzylOxy-3-Fluoro-Bromobenzene is used as a building block for the development of new drugs. Its reactivity and the presence of multiple functional groups allow for the synthesis of a wide range of pharmaceutically relevant molecules.
Used in Chemical Research:
4-BenzylOxy-3-Fluoro-Bromobenzene is also utilized in chemical research as a model compound for studying the properties and reactions of organobromides and phenols. This helps researchers understand the behavior of these compounds and develop new synthetic strategies and applications.

InChI:InChI=1/C13H10BrFO/c14-11-6-7-13(12(15)8-11)16-9-10-4-2-1-3-5-10/h1-8H,9H2

Upstream product

• 2105-94-4 4-bromo-2-fluorophenol 
• 100-39-0 benzyl bromide 
• 100-44-7 benzyl chloride 
• 96693-06-0 4-(n-octyloxy)-iodobenzene 
• 348-61-8 1-bromo-3,4-difluorobenzene 
• 100-51-6 benzyl alcohol 
• 367-12-4 2-fluorophenol 
• 121219-03-2 4-bromo-3-fluorophenol 
• 368-21-8 2-fluorophenyl phenylmethyl ether 

Downstream Products

• 152552-64-2 4-(benzyloxy)-3-fluorobenzoic acid 
• 839694-31-4 methyl 3-(4-(benzyloxy)-3-fluorophenyl)acrylate 
• 847231-07-6 1-(4-benzyloxy-3-fluorophenyl)-2-methyl-1H-indole 
• 839694-38-1 7-fluoro-1-oxaspiro[4.5]deca-6,9-dien-8-one 
• 839694-33-6 2-fluoro-4-(3-hydroxypropyl)phenol 
• 839694-48-3 7-fluorochroman-6-ol 
• 590417-24-6 3-(3-fluoro-4-hydroxyphenyl)propionic acid methyl ester 
• 179066-16-1 3-Fluoro-4-hydroxy-benzoic acid (R)-1-ethyl-heptyl ester 
• 179066-15-0 4-Benzyloxy-3-fluoro-benzoic acid (R)-1-ethyl-heptyl ester 
• 216880-04-5 8-(4-benzyloxy-3-fluorophenyl)-1,4-dioxaspiro[4.5]decan-8-ol 
• 1181566-72-2 1-{3-fluoro-4-[(phenylmethyl)oxy]phenyl}-4-[(phenylmethyl)oxy]-1H-indole 
• 133057-83-7 4-benzyloxy-3-fluorophenylboronic acid 
• 175968-61-3 3-fluoro-4-[(phenylmethyl)oxy]benzaldehyde 
• 1338327-54-0 4-amino-6-(3-fluoro-4-hydroxyphenyl)-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5(6H)-one 

Relevant articles and documents

Fluorinated Radicamine A and B: Synthesis and Glycosidase Inhibition

Fluorinated derivatives of radicamine A and radicamine B have been synthesized from D-arabinose-derived cyclic nitrone. Structure-activity relationship studies showed that glycosidase inhibition of these fluorinated derivatives was significantly influenced by the position of the fluorine atom. C-7 or C-11 fluorination of the aromatic ring decreased α-glucosidase inhibition of the derivatives, whereas C-8 or C-10 fluorination preserved glycosidase inhibitory activities. Fluorinated derivatives of radicamine A and B have been synthesized from D-arabinose-derived cyclic nitrone. Structure-activity relationship studies revealed that glycosidase inhibition of these fluorinated derivatives was significantly influenced by the position of the fluorine atom.

List fluoro Radicamine compounds and their use and preparation method

The invention discloses a mono-fluorinated Radicamine compound which has a structure as shown in a formula (1), and further provides a preparation method for the mono-fluorinated Radicamine compound with the structure as shown in the formula (1) and an application of the mono-fluorinated Radicamine compound or the mono-fluorinated Radicamine compound prepared with the method to preparation of drugs for preventing and/or treating diabetes, drugs for preventing and/or treating Gaucher's diseases, drugs for preventing and/or treating tumors or antiviral drugs. The mono-fluorinated Radicamine compound provided by the invention is good in glycosidase inhibition activity.

TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE

Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.

NOVEL TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

The invention provides novel compounds having the general formula (I): wherein R1, R2, R3, Q, U,W, Z, X and Y are as described herein, compositions including the compounds and methods of using the compounds. These compounds are HbsAg inhibitors and are useful as medicaments for the treatment or prophylaxis of HBV infection.

[...] compd. mesogene medium

The invention relates to bimesogenic compounds of formula I wherein R11, R12, MG11, MG12, X11, X12 and Sp1 have the meaning given in claim 1, to the use of bimesogenic compounds of formula I in liquid crystal media and particular to flexoelectric liquid crystal devices comprising a liquid crystal medium according to the present invention. Furthermore the invention relates to bimesogenic compounds of formula I inducing a second nematic phase in nematic mixtures that do not show this additional phase without compounds of formula I.

THIOARYL DERIVATIVES AS GPR120 AGONISTS

The present invention relates to thioaryl derivatives of Formula 1 as defined in the specification, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The thioaryl derivatives of Formula 1 according to the present invention promote GLP-1 formation in the gastrointestinal tract and improve insulin resistance in macrophages, pancreas cells, etc. due to anti-inflammatory action, and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, inflammation, obesity, non-alcoholic fatty liver, steatohepatitis or osteoporosis.

CYCLOALKYLAMINE DERIVATIVE

Provided is a therapeutic agent for hyperparathyroidism, renal osteodystrophy, hypercalcemia and the like, which has a CaSR activating (agonist) action. A compound represented by the following general formula (1): [wherein, Ar which is a partial structure

P-Hydroxyphenacyl photoremovable protecting groups Robust photochemistry despite substituent diversity

A broadly based investigation of the effects of a diverse array of substituents on the photochemical rearrangement of p-hydroxyphenacyl esters has demonstrated that common substituents such as F, MeO, CN, CO2R, CONH2, and CH3 have little effect on the rate and quantum efficiencies for the photo-Favorskii rearrangement and the release of the acid leaving group or on the lifetimes of the reactive triplet state. A decrease in the quantum yields across all substituents was observed for the release and rearrangement when the photolyses were carried out in buffered aqueous media at pHs that exceeded the ground-state pKa of the chromophore where the conjugate base is the predominant form. Otherwise, substituents have only a very modest effect on the photoreaction of these robust chromophores.

LIQUID-CRYSTALLINE COMPOUNDS AND LIQUID-CRYSTALLINE MEDIA

The present invention relates to liquid-crystalline compounds having at least three fluorine-substituted benzene rings, a terminal trifluoromethyl group and at least one —CF2O— bridge. The invention also relates to liquid-crystalline media prep

[1,2,4] TRIAZOLO [4,3-B] PYRIDAZINES AS LIGANDS OF THE ANDROGEN RECEPTOR

The invention concerns bicyclic compounds of Formula (I): wherein, R1, R2, R3, R4, R5, X1, X2, Y, k, m, n and p are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the treatment of androgen- receptor associated conditions, particularly prostate cancer.